体外研究 (In Vitro) |
QL-X-138 (72 h) exhibits anti-proliferation activity against lymphoma and leukemia cell lines, with an GI50s of 0.31, 1.2, 0.49,1.4, 0.4, 0.23, 0.95, 1.2, 1.4, 0.23, 1.3, 0.93, 1, and 2.4 μM for TMD8, U2932, Ramos, OCI-AML3, SKM-1, NOMO-1, NB4, HEL, U937, NALM6, MEC-1, MEC-2, Hs 505.T and REC-1 cells, respectively[1]. QL-X-138 (0.5-5 μM; 24-72 h) arrests the progression of Ramos, OCI-AML-3, U937 and U2932 cells cycle in a dose dependent manner[1]. QL-X-138 (0.5-5 μM; 8-72 h) induces apoptosis of Ramos, OCI-AML-3, U937 and U2932 cells in a time- and dose-dependent manner[1]. QL-X-138 (3-10000 nM; 4 h) blocks BTK- and MNK-mediated signaling in lymphoma and leukemia cell[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis[1]
Cell Line: |
Ramos, OCI-AML3, U2932, TMD8 and U937 cells |
Concentration: |
3, 10, 30, 100, 300, 1000, 3000, 10000 nM |
Incubation Time: |
4 hours |
Result: |
Significantly suppressed BTK auto-phosphorylation of Y223 (EC50=11 nM). Strongly blocked phosphorylation of the BTK downstream target PLCγ2 Y1217 (EC50=57 nM). Suppressed the phosphorylation of the MNK downstream target eIF4E S209 at a concentration of 1 μM. |
|